赛隆药业(002898) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥69,484,400.80, a decrease of 12.52% compared to ¥79,427,813.05 in the same period last year[5] - Net profit attributable to shareholders was ¥1,624,090.66, down 49.21% from ¥3,197,374.56 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0092, a decrease of 49.45% from ¥0.0182 in the same period last year[5] - Net profit for the current period is ¥1,624,090.66, down 49.2% from ¥3,197,374.56 in the previous period[18] - Total operating revenue for the current period is ¥69,484,400.80, a decrease of 12.4% from ¥79,427,813.05 in the previous period[17] - Total operating costs decreased to ¥66,306,449.91 from ¥78,468,996.00, reflecting a reduction of 15.5%[17] - Sales revenue from goods and services received cash of ¥33,345,291.71, down 50.2% from ¥67,006,626.11 in the previous period[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥17,436,292.79, representing a decline of 214.04% compared to -¥5,552,217.03 in the previous year[5] - Cash flow from operating activities shows a net outflow of ¥17,436,292.79, compared to a smaller outflow of ¥5,552,217.03 in the previous period[19] - Cash flow from investment activities generated a net inflow of ¥1,187,045.07, contrasting with a net outflow of ¥5,116,248.02 in the previous period[19] - Cash and cash equivalents at the end of the period totaled ¥54,532,212.02, compared to ¥46,377,644.90 at the end of the previous period[20] - Cash and cash equivalents decreased from CNY 87,118,672.26 to CNY 56,544,816.92, a decline of approximately 35.1%[14] Assets and Liabilities - Total assets at the end of the reporting period were ¥784,307,744.04, down 3.63% from ¥813,843,574.35 at the end of the previous year[5] - Current assets decreased from CNY 256,302,322.01 to CNY 231,100,641.49, representing a reduction of about 9.8%[14] - Total liabilities decreased from CNY 277,961,889.44 to CNY 246,801,968.47, reflecting a decline of about 11.2%[15] - The equity attributable to the owners of the parent company increased slightly from CNY 535,881,684.91 to CNY 537,505,775.57, an increase of approximately 0.3%[16] - Short-term borrowings decreased from CNY 90,047,819.38 to CNY 80,013,097.16, a decline of about 11.3%[15] - The company’s long-term borrowings decreased from CNY 25,080,000.00 to CNY 22,840,000.00, a reduction of about 9.0%[15] Accounts Receivable and Prepayments - The company reported a 69.17% increase in accounts receivable, primarily due to increased credit sales during the reporting period[8] - Accounts receivable increased from CNY 28,390,203.22 to CNY 48,029,078.43, showing a significant rise of about 69.5%[14] - The company experienced a 77.23% increase in prepayments, mainly due to new clinical trial fees and financing costs incurred during the period[8] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,854, with the largest shareholder holding 51.15% of the shares[10] Research and Development - The company reported a significant increase in research and development expenses, totaling ¥5,344,923.89, compared to ¥7,277,255.13 in the previous period[17] Non-Operating Income - The company recorded a non-operating income of ¥763,790.51 from non-recurring gains, including asset disposal and government subsidies[6] Other Information - The company has not reported any new product launches or significant market expansions during this quarter[21]